Hemab Therapeutics (NASDAQ:COAG) Releases Quarterly Earnings Results

Hemab Therapeutics (NASDAQ:COAG) issued its quarterly earnings data on Thursday. The company reported ($23.98) earnings per share for the quarter, Zacks reports.

Hemab Therapeutics Stock Down 1.6%

Shares of COAG opened at $25.89 on Friday. Hemab Therapeutics has a 12 month low of $23.00 and a 12 month high of $36.61.

Insider Buying and Selling

In other news, major shareholder Ra Capital Management, L.P. purchased 3,802 shares of the business’s stock in a transaction on Tuesday, May 19th. The shares were acquired at an average price of $24.97 per share, with a total value of $94,935.94. Following the completion of the transaction, the insider owned 6,375,972 shares of the company’s stock, valued at $159,208,020.84. The trade was a 0.06% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have acquired a total of 2,902,872 shares of company stock worth $53,769,784 over the last quarter.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.